MP64-04 IDENTIFYING SKELETAL-RELATED EVENTS FOR PROSTATE CANCER IN ROUTINELY COLLECTED HOSPITAL DATA

Abstract

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History II (MP64)1 Apr 2020MP64-04 IDENTIFYING SKELETAL-RELATED EVENTS FOR PROSTATE CANCER IN ROUTINELY COLLECTED HOSPITAL DATA Matthew Parry*, Thomas Cowling, Arunan Sujenthiran, Julie Nossiter, Brendan Berry, Paul Cathcart, Noel Clarke, Heather Payne, Ajay Aggarwal, and Jan van der Meulen Matthew Parry*Matthew Parry* More articles by this author , Thomas CowlingThomas Cowling More articles by this author , Arunan SujenthiranArunan Sujenthiran More articles by this author , Julie NossiterJulie Nossiter More articles by this author , Brendan BerryBrendan Berry More articles by this author , Paul CathcartPaul Cathcart More articles by this author , Noel ClarkeNoel Clarke More articles by this author , Heather PayneHeather Payne More articles by this author , Ajay AggarwalAjay Aggarwal More articles by this author , and Jan van der MeulenJan van der Meulen More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000939.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Non-osteoporotic skeletal-related events (SREs) are clinically important markers of disease progression in prostate cancer. We developed and validated an approach to identify SREs in men with prostate cancer using routinely-collected data. METHODS: Patients diagnosed with prostate cancer between January 2010 and December 2013 were identified in the National Prostate Cancer Audit, based on English cancer registry data. A coding framework was developed based on diagnostic and procedure codes in linked national administrative hospital and routinely-collected radiotherapy data to identify SREs occurring before December 2015. Two coding definitions of SREs were assessed based on whether the SRE codes were paired with a bone metastasis code (‘specific definition’) or used in isolation (‘sensitive definition’). We explored the validity of both definitions by comparing the cumulative incidence of SREs from time of diagnosis according to prostate cancer stage at diagnosis with death as a competing risk. RESULTS: We identified 40,063, 25,234 and 13,968 patients diagnosed with localised, locally advanced and metastatic disease, respectively. Using the specific definition, we found that the 5-year cumulative incidence of SREs was 0.9% in patients with localised disease, 5.4% in patients with locally advanced disease, and 38.8% in patients with metastatic disease. Using the sensitive definition, the corresponding cumulative incidence figures were 8.4%, 13.4%, and 40.7%, respectively. CONCLUSIONS: The comparison of the cumulative incidence of SREs identified in routinely collected hospital data, based on a specific coding definition in patients diagnosed with different prostate cancer stage, supports their validity as a clinically important marker of cancer progression. Source of Funding: M.G.P. was supported by a Doctoral Research Fellowship from the NHS National Institute for Health Research (DRF-2018-11-ST2-036). T.E.C. was supported by the Medical Research Council (MR/S020470/1). B.B. was partly supported by the NHS National Institute for Health Research through an Academic Clinical Fellowship. H.P. was supported by the University College London Hospitals/University College London Comprehensive Biomedical Research Centre. J.v.d.M. was partly supported by the NIHR Collaboration for Leadership in Applied Health Research and Care North Thames at Bart’s Health NHS Trust. The views expressed in this article are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e964-e964 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Matthew Parry* More articles by this author Thomas Cowling More articles by this author Arunan Sujenthiran More articles by this author Julie Nossiter More articles by this author Brendan Berry More articles by this author Paul Cathcart More articles by this author Noel Clarke More articles by this author Heather Payne More articles by this author Ajay Aggarwal More articles by this author Jan van der Meulen More articles by this author Expand All Advertisement PDF downloadLoading ...